Paper Details

  1. Home
  2. Paper Details

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Author: BlomDirk J, CharngMin-Ji, Chasan-TaberScott, CromwellWilliam C, CrookeStanley T, FlaimJoann D, GaudetDaniel, LachmannRobin H, MaraisA David, RaalFrederick J, SantosRaul D, TanJu L, TribbleDiane L

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Mipomersen is an antisense inhibitor of apolipoprotein B synthesis that is used to lower LDL cholesterol levels in patients with homozygous familial hypercholesterolaemia. This study investigated the effectiveness and safety of mipomersen as an adjunctive treatment for this condition.
Paper Details　
Original Abstract of the Article :
Homozygous familial hypercholesterolaemia is a rare genetic disorder in which both LDL-receptor alleles are defective, resulting in very high concentrations of LDL cholesterol in plasma and premature coronary artery disease. This study investigated whether an antisense inhibitor of apolipoprotein B ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(10)60284-X

データ提供：米国国立医学図書館（NLM）

Mipomersen: A New Hope for Homozygous Familial Hypercholesterolaemia

The realm of [lipid metabolism] presents unique challenges when addressing [homozygous familial hypercholesterolaemia], a rare genetic disorder characterized by extremely high levels of [LDL cholesterol]. This study investigates the efficacy and safety of [mipomersen], an [antisense inhibitor of apolipoprotein B synthesis], as an adjunctive therapy to lower [LDL cholesterol] in patients with this debilitating condition. The authors demonstrate the potential of [mipomersen] to significantly reduce [LDL cholesterol] levels, offering a glimmer of hope for patients facing the devastating consequences of this disease.

A Ray of Light in the Desert of Hypercholesterolaemia

The authors shed light on the potential of [mipomersen] to offer significant benefits for patients with [homozygous familial hypercholesterolaemia]. This research provides a glimmer of hope in the desert of this rare and challenging condition, offering a promising new treatment option for those affected by this debilitating disease.

Navigating the Desert of Lipid Management: A New Tool for Clinicians

This research equips clinicians with a valuable new tool to combat the challenges of [homozygous familial hypercholesterolaemia]. The authors provide evidence-based information to guide treatment decisions, demonstrating the efficacy and safety of [mipomersen] in lowering [LDL cholesterol] levels. This research provides an oasis of knowledge in the vast desert of lipid management.

Dr.Camel's Conclusion

This study is a reminder that even in the most desolate areas of medical knowledge, we can find hope and innovation. The development of [mipomersen] represents a significant step forward in the treatment of [homozygous familial hypercholesterolaemia], offering a glimmer of hope for patients facing a challenging journey. Let us embrace this research as a reminder to never cease exploring the vast desert of medical knowledge, seeking new solutions to improve patient outcomes.

Date :
  1. Date Completed 2010-05-03
  2. Date Revised 2015-06-16
Further Info :

Pubmed ID

20227758

DOI: Digital Object Identifier

10.1016/S0140-6736(10)60284-X

Related Literature

Article Analysis
・Effects of mipomersen injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.